Vantage 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong
Biopharma and medtech painted a mixed picture in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing activity, and FDA drug approvals.
Download your copy of Vantage Pharma, Biotech and Medtech 2018 in Review to understand which areas struggled or succeeded and what this means for 2019.
Stock market performance was underwhelming at best –The Nasdaq Biotechnology Index grew 15% before suffering a painful Q4, resulting in a 9% year-end decline, while the S&P Pharmaceuticals Index only managed a 5% gain.
M&A and product licensing volumes were notably low, despite high-profile deals by Takeda and Bristol-Myers Squibb
The total value of medtech M&A deals came to $27.4bn, a 75% decline from 2017, while the 196 medtech VC deals completed was the fewest in more than a decade